The people behind Syngenis

Professor Veedu is the founder of Syngenis and an internationally recognised expert in DNA and RNA chemistry, oligonucleotide therapeutics, and nucleic-acid modification. He serves as Professor and Head of the Precision Nucleic Acid Therapeutics Group within Murdoch University's Personalised Medicine Centre and the Perron Institute for Neurological and Translational Science.

Professor Veedu has more than two decades of experience in basic and translational research in nucleic-acid technologies, focusing on advancing DNA and RNA science from laboratory research into practical diagnostic and therapeutic applications. His leadership has spanned state-of-the-art synthesis facilities and long-term research programs in Australia, with direct operational experience…

Dr Blake is a practising radiologist and experienced healthcare executive with a strong background in medical technology, diagnostics, and governance. He brings extensive board-level experience across listed and private healthcare companies, with particular expertise in regulated clinical environments.

Dr Blake is currently Chair of the WA National Imaging Facility Advisory Board, and until recently served as Chairman of Resonance Health Ltd (ASX:RHT), a listed medical technology company specialising in advanced imaging and diagnostic software. His experience includes oversight of regulatory strategy, clinical adoption, commercialisation, and engagement with hospital networks and healthcare providers.

Across his board roles, Dr Blake has been…

Thomas Hanly is a biotechnology executive with experience forming and scaling science-led businesses across diagnostics and life sciences, with a strong focus on translating early-stage research into commercially viable platforms.

Mr Hanly was recently a founding director of Nexsen Limited (ASX:NXN), a biotechnology diagnostics company that has since listed on the ASX. During its early stages, he was closely involved in hands-on operational execution, including working with university research groups, structuring collaboration and licence agreements, and progressing early research outcomes into defined diagnostic technologies suitable for commercial application.

He also brings practical experience in securing and managing government grants, research…

Gavin Ball is an experienced business executive and director with more than 30 years of hands-on experience in company formation, commercial development, growth strategy, and operational management across ASX-listed and private companies.

Mr Ball has extensive experience in ASX-listed agribusiness through his involvement with RLF AgTech Ltd (ASX:RLF), where he has supported strategy, governance, and commercial execution within a regulated, export-focused agricultural technology business. He also brings listed resources sector experience as a founding and original board member of McLaren Minerals Limited (ASX:MML), contributing to early-stage company development and public market governance.

In the life sciences sector, Mr Ball was…